DOI:
10.1055/s-00000175
Arzneimittelforschung
LinksClose Window
References
Ravandi F, O’Brien S, Thomas D et al.
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Blood 2010;
116: 2070-2077
We do not assume any responsibility for the contents of the web pages of other providers.